Scarica l'app Stockscreener
1.74
3.60%
-0.065
Dopo l'orario di chiusura:
1.78
0.04
+2.30%
Precedente Chiudi:
$1.805
Aprire:
$1.74
Volume 24 ore:
19,391
Relative Volume:
0.77
Capitalizzazione di mercato:
$9.62M
Reddito:
-
Utile/perdita netta:
$-14.29M
Rapporto P/E:
-0.4361
EPS:
-3.99
Flusso di cassa netto:
$-12.27M
1 W Prestazione:
+4.19%
1M Prestazione:
+2.35%
6M Prestazione:
-40.00%
1 anno Prestazione:
-62.23%
Intervallo 1D:
$1.74
$1.83
Intervallo di 1 settimana:
$1.6172
$1.9732
Portata 52W:
$1.412
$5.01
Aprea Therapeutics Inc Stock (APRE) Company Profile
Nome
Aprea Therapeutics Inc
Settore
Industria
Telefono
215-948-4119
Indirizzo
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Confronta APRE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
APRE
Aprea Therapeutics Inc
|
1.74 | 9.24M | 0 | -14.29M | -12.27M | -3.99 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-12-28 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | Iniziato | Berenberg | Buy |
| 2020-09-29 | Ripresa | JP Morgan | Neutral |
| 2020-06-22 | Iniziato | H.C. Wainwright | Neutral |
| 2020-04-21 | Iniziato | Robert W. Baird | Outperform |
| 2019-10-28 | Iniziato | JP Morgan | Neutral |
| 2019-10-28 | Iniziato | Morgan Stanley | Equal-Weight |
| 2019-10-28 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Aprea Therapeutics Inc Borsa (APRE) Ultime notizie
Acute Myeloid Leukemia Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight - openPR.com
Ovarian Cancer Drugs Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight - openPR.com
Q2 Earnings Estimate for APRE Issued By Wedbush - Defense World
Eton Pharmaceuticals (NASDAQ:ETON) Earns “Buy” Rating from B. Riley - Defense World
The Manufacturers Life Insurance Company Sells 752 Shares of Pediatrix Medical Group, Inc. (NYSE:MD) - Defense World
The Manufacturers Life Insurance Company Purchases 993 Shares of CTO Realty Growth, Inc. (NYSE:CTO) - Defense World
InMode Ltd. (NASDAQ:INMD) Shares Sold by The Manufacturers Life Insurance Company - Defense World
What is Wedbush’s Estimate for ORKA FY2029 Earnings? - Defense World
Roth Capital Has Bearish Forecast for TENX FY2028 Earnings - Defense World
Petro-Victory Energy Corp. Announces Short Term Loan - Barchart.com
Stocks Close Higher On Optimism Over US Trade Negotiations - Barchart.com
Ontario Lottery And Gaming CorporationMidDay Lottery Winning NumbersMay 16, 2025 - Barchart.com
Becton, Dickinson And Company Stock: Analyst Estimates & Ratings - Barchart.com
CORRECTION FROM SOURCE: Adia Nutrition Inc. Successfully Uplists to OTCQB Venture Market in Record-Breaking Six Weeks and Completes SEC Rule 15c2-11 Compliance - Barchart.com
Strathcona Resources Ltd. Reports First Quarter 2025 Financial and Operating Results, Announces Quarterly Dividend and Investment in MEG Energy Corp. - Barchart.com
Aprea Therapeutics Reports Q1 2025 Progress and Financials - TipRanks
NoticeGO-TO DEVELOPMENTS HOLDINGS INC., GO-TO SPADINA ADELAIDE SQUARE INC., FURTADO HOLDINGS INC., and OSCAR FURTADO, File No. 2022-8 - Barchart.com
RBC Global Asset Management Inc. Announces RBC ETF Cash Distributions For May 2025 - Barchart.com
Tower Research Capital LLC TRC Acquires 6,486 Shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) - Defense World
Strathcona Resources Ltd. Announces Sale of Montney Business for $2.84 Billion and Acquisition of Hardisty Rail Terminal - Barchart.com
BIG ROCK BREWERY INC. ANNOUNCES RESULTS OF ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS - Barchart.com
Psychemedics Named “Most Innovative Drug Testing Company Of The Year” - Barchart.com
This Under-The-Radar Cancer Biotech Reports 21% Tumor Shrinkage: Analysts See 600%+ Upside - Barchart.com
GFL Environmental Inc. Announces Results From Annual General Meeting Of Shareholders - Barchart.com
Aprea (APRE) Reports Q1 Revenue Drop Amid Clinical Progress | AP - GuruFocus
APRE Reports Decrease in Cash Reserves by End of Q1 2025 | APRE Stock News - GuruFocus
Aprea Therapeutics Reports Promising Q1 2025 Results - TipRanks
Aprea Therapeutics reports Q1 EPS (66c) vs. (67c) last year - TipRanks
Aprea Therapeutics, Inc. SEC 10-Q Report - TradingView
Aprea Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update - The Manila Times
Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update - GlobeNewswire Inc.
Stocks In Play: Knight Therapeutics Inc - Barchart.com
NRx Pharmaceuticals (NASDAQ: NRXP) To Report Q1 2025 Results On May 15 - Barchart.com
Aprea Therapeutics Inc expected to post a loss of 86 cents a shareEarnings Preview - TradingView
Stocks In Play: Galiano Gold Inc. - Barchart.com
Stocks In Play: Illumin Holdings Inc. - Barchart.com
PBYI Stock Rises As Q1 Earnings And Sales Beat Estimates - Barchart.com
Japanese Tech Company Panasonic Cuts 4% Of Its Global Workforce As Profits Falter - Barchart.com
LifeSpeak Inc. Announces First Quarter 2025 Results - Barchart.com
Stocks In Play: Knight Therapeutics Inc. - Barchart.com
PIZZA PIZZA ROYALTY CORP. ANNOUNCES FIRST QUARTER 2025 RESULTS - Barchart.com
Adicet Bio Advances Two Breakthrough Therapies: Key Clinical Data Coming in 2025 for Lupus and Cancer Programs - Stock Titan
Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates - Business Wire
IGM FINANCIAL INC. ANNOUNCES APRIL 2025 ASSETS UNDER MANAGEMENT & ADVISEMENT AND NET FLOWS - Barchart.com
Larimar Therapeutics Reports Q1 2025 Results and Advances Nomlabofusp Development - MyChesCo
LPL Financial LLC Makes New $53,000 Investment in Aprea Therapeutics, Inc. (NASDAQ:APRE) - Defense World
3 Consumer Discretionary Stocks to Buy in a Divided Economy - The Globe and Mail
Carnival Corporation Earnings Preview: What To Expect - Barchart.com
Repare Therapeutics Inc.'s (NASDAQ:RPTX) Shares Bounce 30% But Its Business Still Trails The Industry - simplywall.st
Prelude Therapeutics Unveils Promising Preclinical Data on Novel Cancer Therapies - MyChesCo
Aprea Therapeutics Inc Azioni (APRE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.89%
3.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):